Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.
Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.
复制标题
DOI：
10.1007/s00262-018-2256-3
复制
发表时间：
2019-03
期刊：
影响因子：
--
通讯作者：
Brenner JC
中科院分区：
文献类型：
--
作者：
Mann JE;Smith JD;Birkeland AC;Bellile E;Swiecicki P;Mierzwa M;Chinn SB;Shuman AG;Malloy KM;Casper KA;McLean SA;Moyer JS;Wolf GT;Bradford CR;Prince ME;Carey TE;McHugh JB;Spector ME;Brenner JC
复发性喉鳞状细胞癌(LSCCs)预后较差，没有可靠的生物标志物来确定哪些患者可能从辅助治疗中受益。鉴于肿瘤浸润性淋巴细胞(TIL)在头颈部鳞状细胞癌中作为生物标志物的出现，我们建立了预测性模型来了解CD4+、CD8+和/或CD103+TIL状态在晚期LSCC患者中的作用。从183例复发/持续性LSCC患者的残留性喉切除标本中构建组织芯片，分别对CD4+、CD8+和CD103+TIL含量进行染色。COX比例风险回归分析用于评估CD4+、CD8+和CD103+TIL水平的组合对复发/持续性LSCC患者的总生存期(OS)、疾病特异性生存期(DSS)和无病生存期(DFS)的预测作用。肿瘤CD103+TIL含量高与OS、DSS和DFS显著改善相关，与CD8+或CD4+TIL含量高相比，高CD103+TIL含量是复发/持续性LSCC患者更强的生存预测因子。在多变量分析中，肿瘤中同时富含CD103+和CD4+TIL的“免疫丰富”表型在复发/持续的喉癌中提供了生存益处(OS风险比：0.28，p=0.0014；DSS风险比：0.09，p=0.0015；DFS风险比：0.18，p=0.0018)。CD103+TIL含量所驱动的免疫模式，单独和结合CD4+TIL含量，是复发/持续性LSCC患者预后的生物标志物。因此，本文描述的预测模型在预后分层中可能被证明是有价值的，并导致针对这一患者群体的个性化治疗范例。CD103+肿瘤浸润性淋巴细胞是一种强有力的免疫标记物，与提高复发性喉鳞状细胞癌的存活率有关。此生物标志物可能对个体化预测和治疗选择有价值。
Recurrent laryngeal squamous cell carcinomas (LSCCs) are associated with poor outcomes, without reliable biomarkers to identify patients who may benefit from adjuvant therapies. Given the emergence of tumor infiltrating lymphocytes (TIL) as a biomarker in head and neck squamous cell carcinoma, we generated predictive models to understand the utility of CD4+, CD8+ and/or CD103+ TIL status in patients with advanced LSCC. Tissue microarrays were constructed from salvage laryngectomy specimens of 183 patients with recurrent/persistent LSCC and independently stained for CD4+, CD8+, and CD103+ TIL content. Cox proportional hazards regression analysis was employed to assess combinations of CD4+, CD8+, and CD103+ TIL levels for prediction of overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) in patients with recurrent/persistent LSCC. High tumor CD103+ TIL content was associated with significantly improved OS, DSS, and DFS and was a stronger predictor of survival in recurrent/persistent LSCC than either high CD8+ or CD4+ TIL content. On multivariate analysis, an “immune-rich” phenotype, in which tumors were enriched for both CD103+ and CD4+ TILs, conferred a survival benefit (OS hazard ratio: 0.28, p = 0.0014; DSS hazard ratio: 0.09, p = 0.0015; DFS hazard ratio: 0.18, p = 0.0018) in recurrent/persistent LSCC. An immune profile driven by CD103+ TIL content, alone and in combination with CD4+ TIL content, is a prognostic biomarker of survival in patients with recurrent/persistent LSCC. Predictive models described herein may thus prove valuable in prognostic stratification and lead to personalized treatment paradigms for this patient population. CD103+ tumor infiltrating lymphocytes signify a robust immune marker associated with improved survival in recurrent laryngeal squamous cell carcinomas. This biomarker may be of value for individualized prognostication and treatment selection.
登录
查看更多内容
影响因子：
10.1
作者：
Solomon, Benjamin;Young, Richard J.;Rischin, Danny
通讯作者：
Rischin, Danny
影响因子：
2.6
作者：
Wansom, Derrick;Light, Emily;Thomas, Dafydd;Worden, Francis;Prince, Mark;Urba, Susan;Chepeha, Douglas;Kumar, Bhavna;Cordell, Kitrina;Eisbruch, Avraham;Taylor, Jeremy;Moyer, Jeffrey;Bradford, Carol;D'Silva, Nisha;Carey, Thomas;McHugh, Jonathan;Wolf, Gregory
通讯作者：
Wolf, Gregory
DOI：
10.1002/hed.24918
发表时间：
2017-12
期刊：
Head & neck
影响因子：
--
作者：
Birkeland AC;Beesley L;Bellile E;Rosko AJ;Hoesli R;Chinn SB;Shuman AG;Prince ME;Wolf GT;Bradford CR;Brenner JC;Spector ME
通讯作者：
Spector ME
复发和转移性头颈癌的分子景观：精确肿瘤学测序平台的见解。
影响因子：
28.4
作者：
Morris LGT;Chandramohan R;West L;Zehir A;Chakravarty D;Pfister DG;Wong RJ;Lee NY;Sherman EJ;Baxi SS;Ganly I;Singh B;Shah JP;Shaha AR;Boyle JO;Patel SG;Roman BR;Barker CA;McBride SM;Chan TA;Dogan S;Hyman DM;Berger MF;Solit DB;Riaz N;Ho AL
通讯作者：
Ho AL
影响因子：
158.5
作者：
WOLF, GT
通讯作者：
WOLF, GT